Lilly taps Lycia for protein degrader tech in $1.6bn dealEli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal Share XLilly taps Lycia for protein degrader tech in $1.6bn dealhttps://pharmaphorum.com/news/lilly-taps-lycia-for-protein-degrader-tech-in-1-6bn-deal/
Akili adds to ADHD gaming range with $37.5m TALi licensing dealAkili already has the first and only FDA cleared video game-based digital therapeutic (DTx) for children with attention-deficit Share XAkili adds to ADHD gaming range with $37.5m TALi licensing dealhttps://pharmaphorum.com/news/akili-adds-to-adhd-gaming-range-with-37m-tali-licensing-deal/
Amgen pays Kyowa $400m upfront for OX40 eczema drugAmgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim Share XAmgen pays Kyowa $400m upfront for OX40 eczema drughttps://pharmaphorum.com/news/amgen-pays-kyowa-400m-upfront-for-ox40-eczema-drug/
Biogen bolsters ischaemic stroke pipeline with thrombolytic from TMSBiogen has licensed a new drug from Japanese biotech TMS that it hopes could provide a big advance Share XBiogen bolsters ischaemic stroke pipeline with thrombolytic from TMShttps://pharmaphorum.com/news/biogen-bolsters-ischaemic-stroke-pipeline-with-thrombolytic-from-tms/
Merck KGaA offloads failed MEK programme to startup Day OneUS biotech Day One has taken ownership of a cancer drug that has been languishing in Merck KGaA’s Share XMerck KGaA offloads failed MEK programme to startup Day Onehttps://pharmaphorum.com/news/merck-kgaa-offloads-failed-mek-programme-to-startup-day-one/
Lilly adds to pain pipeline with Asahi Kasei licensing dealUS drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has Share XLilly adds to pain pipeline with Asahi Kasei licensing dealhttps://pharmaphorum.com/news/lilly-adds-to-pain-pipeline-with-asahi-kasei-licensing-deal/
Bayer joins the COVID-19 vaccine push, backing CureVac shotShortly after launching large-scale trials of its COVID-19 vaccine candidate, CureVac has the partner it will need to Share XBayer joins the COVID-19 vaccine push, backing CureVac shothttps://pharmaphorum.com/news/bayer-joins-the-covid-19-vaccine-push-backing-curevacs-shot/
Amgen hands off leprosy, TB candidate to Australian non-profitAmgen has decided that a drug for leprosy and tuberculosis it inherited as part of its acquisition of Share XAmgen hands off leprosy, TB candidate to Australian non-profithttps://pharmaphorum.com/news/amgen-hands-off-leprosy-tb-candidate-to-australian-non-profit/
Merck cuts $1bn deal with Janux for cancer T-cell therapiesIn a deal that could top $1 billion, Merck & Co has teamed up with US biotech Janux Share XMerck cuts $1bn deal with Janux for cancer T-cell therapieshttps://pharmaphorum.com/news/merck-cuts-1bn-deal-with-janux-for-cancer-t-cell-therapies/
